LKS advises SAI Parenterals on cross-border acquisition of Noumed Pharmaceuticals

Sai Parenterals Limited has made a cross-border acquisition of 74.6% equity stake in Noumed Pharmaceuticals Pty Ltd (Australia) through a combination of secondary purchase from Noumed Life Sciences Limited (United Kingdom) along with primary subscription by way of a convertible loan.

Lakshmikumaran & Sridharan Attorneys advised and acted for Sai Parenterals and its Singapore subsidiary, Sai Parenterals Pte Limited, on this acquisition. The Firm provided comprehensive end-to-end legal support across all stages of the transaction, including drafting, review, negotiation, and finalisation of a suite of complex transaction documents. The Firm played a central role in coordinating and managing the closing process and liaising with multiple stakeholders across jurisdictions to facilitate a seamless completion.

The transaction team from consisted of Noorul Hassan (Executive Partner), Shipra Verma (Associate Partner) and Alekhya Kanda (Senior Associate).

SAI Parenterals an Indian pharmaceutical company with a proven track record in the formulations segment which operates across the pharmaceutical value chain, including research & development (R&D), manufacturing, regulatory compliance, marketing, and exports.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.